2022
DOI: 10.1097/coc.0000000000000911
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei

Abstract: Pseudomyxoma peritonei is an infrequent solid tumor in clinical practice. The low morbidity and deficient understanding of this mucus-secreting malignant disease increase the risks of delayed identification or uncontrollable deterioration. In quite a lot cases, patients go through complete cytoreduction surgery and hyperthermic intraperitoneal chemotherapy could receive a long time survival over 5 years. But the recurrence rate is also hard to overlook. Unlike other types of cancer, the standard treatment for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 111 publications
(226 reference statements)
0
2
0
Order By: Relevance
“…That had also improved people’s confidence in the effectiveness of chemotherapy for MARP. In addition, the research of Ye S et al [ 9 ] shows that intraperitoneal hyperthermic perfusion chemotherapy has a good effect on peritoneal pseudomyxoma. This also increases the treatment methods and treatment confidence for patients with intraperitoneal metastasis of MARP.…”
Section: Discussionmentioning
confidence: 99%
“…That had also improved people’s confidence in the effectiveness of chemotherapy for MARP. In addition, the research of Ye S et al [ 9 ] shows that intraperitoneal hyperthermic perfusion chemotherapy has a good effect on peritoneal pseudomyxoma. This also increases the treatment methods and treatment confidence for patients with intraperitoneal metastasis of MARP.…”
Section: Discussionmentioning
confidence: 99%
“…The Peritoneal Surface Oncology Group International (PSOGI) classification, which has been validated on several occasions ( 7 , 8 ), divides PMP into four groups based on histological characteristics: i) acellular mucin (AM), ii) low-grade mucinous carcinoma (LG-PMP), iii) high-grade mucinous carcinoma (HG-PMP), and iv) PMP with the presence of signet ring cells (SRC) ( 4 ). However, histopathology does not completely predict tumor behavior ( 9 ). On the other hand, mucin from PMP is classified into soft, semi-hard, and hard mucin samples based on physical and chemical properties as well as visual appearance ( 10 ).…”
Section: Introductionmentioning
confidence: 99%